ArticleInternational journal of surgery case reports2025
Open surgical revascularization after IL-6 blockade for Takayasu arteritis: A case report.
Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTakayasu arteritis (TAK) is a rare large-vessel vasculitis that may cause critical supra-aortic stenosis and cerebral ischaemia. Guidance on the optimal sequencing of biologic therapy and open revascularisation remains limited. CASE PRESENTATION: A 27-year-old woman with a decade-long history of systemic symptoms and limb claudication developed headaches, dizziness and presyncope. Examination showed asymmetric blood pressure, diminished pulses and widespread bruits. CT angiography demonstrated diffuse aortic wall thickening with critical bilateral carotid stenosis; PET/CT confirmed active vasculitis. High-dose methylprednisolone was started, followed by tapering prednisolone and methotrexate. Persisting symptoms and critical carotid disease prompted starting tocilizumab at week 4, achieving remission at week 10. Three months following therapy initiation, an ascending aorta-to-left carotid bypass with a 12-mm graft was performed via partial upper sternotomy without complications. Neurological symptoms resolved and cerebral flow normalised; she remains relapse-free two years later on tocilizumab, methotrexate and low-dose prednisolone. CLINICAL DISCUSSION: Intravenous tocilizumab rapidly induces remission in TAK and shows lower relapse rates than the subcutaneous route. For long-segment supra-aortic lesions in TAK, open bypass avoids inflamed segments and offers greater durability than endovascular techniques, but should be scheduled during metabolic quiescence to minimise restenosis. This case illustrates the benefit of combining IL-6 blockade with timely surgery.
conclusionOpen surgical revascularisation offers superior long-term patency in extensive Takayasu arteritis, and can be safely performed once remission has been induced with tocilizumab in refractory disease. Multidisciplinary coordination of biologic therapy and open revascularisation may optimise neurological and vascular outcomes in complex supra-aortic TAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.